Methylation of the Promoter Region of the Tight Junction Protein-1 by DNMT1 Induces EMT-like Features in Multiple Myeloma

Miao Li,1,2,6 Lin Qi,2,6 Jing-Bo Xu,3,6 Li-Ye Zhong,1 Szehoi Chan,2 Shu-Na Chen,2 Xin-Rong Shao,2 Li-Yuan Zheng,2 Zhao-Xia Dong,2 Tian-Liang Fang,2 Zhi-Ying Mai,1,2 Juan Li,5 Yongjiang Zheng,1 and Xing-Ding Zhang2

INTRODUCTION

Multiple myeloma (MM) is an incurable disorder, characterized by clonal multiplication of malignant plasma cells. Despite the recent development of multiple anti-MM agents with better overall survival rates,1 MM still poses a great challenge in its clinical management. With the rapid increase in the incidence of MM, novel and molecular therapies against MM are urgently needed.

The molecular alterations that initiate the development of multiple myeloma (MM) are not fully understood. Our results revealed that TJP1 was downregulated in MM and positively related to the overall survival of MM patients in The Cancer Genome Atlas (TCGA) database and patient samples. In parallel, cell adhesion capacity representing MM metastasis was decreased in MM patients compared with healthy samples, together with the significantly activated epithelial-to-mesenchymal transition (EMT) transcriptional-like patterns of MM cells. Further analyses demonstrated that TJP1 negatively regulated EMT and consequently positively regulated cell adhesion in MM from TCGA database and MM1s cells. Furthermore, the methylation level of each CpG site on the TJP1 promoter was negatively correlated with TJP1 expression levels. Quantitative real-time PCR and western blot assays demonstrated that methylase DNMT1 regulated the methylation of TJP1. Finally, treatment with a combination of the MM clinical medicine bortezomib, methylation inhibitor, or TJP1 overexpression significantly suppressed the viability and progression of tumor cells of MM orthotopic models. In summary, our results indicate that DNMT1 promotes the methylation of TJP1 promoter, thereby decreasing its expression and regulating the development of EMT-inhibited MM cell adhesion. Therefore, methylation of TJP1 is a potential therapeutic agent to prevent the progression of MM disease.

Received 23 July 2020; accepted 7 October 2020; https://doi.org/10.1016/j.omto.2020.10.004.
6These authors contributed equally to this work
Correspondence: Xing-Ding Zhang, Department of Pharmacology, Molecular Cancer Research Center, School of Medicine, Sun Yat-sen University, Shenzhen 518107, China.
E-mail: zhangx39@mail.sysu.edu.cn
Correspondence: Yongjiang Zheng, Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China.
E-mail: zhengyj5@mail.sysu.edu.cn
Correspondence: Lin Qi, Department of Pharmacology, Molecular Cancer Research Center, School of Medicine, Sun Yat-sen University, Shenzhen 518107, China.
E-mail: qilin23@mail.sysu.edu.cn

© 2020 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dysfunction has been associated with progression and metastasis of many cancers, including MM.17–21 Furthermore, TJP1 promotes actin stress fiber assembly during EMT.22 Our previous study and that of others showed that TJP1 expression is a biomarker for proteasome inhibitor sensitivity in myeloma.23,24 We then hypothesized that downregulation of TJP1 might suppress MM development via inhibition of EMT. Data on whether TJP1 expression is aberrant and the relative mechanisms in MM remain scant.

In addition, aberrant DNA methylation has been shown to be a marker of cancer.25–29 Under normal conditions, DNA methylation patterns ensure proper regulation of gene expression and stable gene silencing. However, in the development of cancer, several tumor-suppressor genes were shown to be silenced by abnormal DNA methylation.30,31 Furthermore, aberrant hypermethylation of the promoter region of TJP1 was observed in murine leukemia cell lines accompanied by the concomitant suppression of the TJP1 expression.21 How the TJP1 is aberrantly methylated in MM is still not fully understood. DNA methyltransferases (DNMTs) are responsible for the establishment and maintenance of methylation patterns. For example, inhibition of DNMT1 could trigger re-expression of tumor suppressor genes, which were silenced by methylation, and induce cell proliferation in human cancers.32–35 DNMT1-mediated MM progression via methylation has been reported.36 The relationship between DNA methyltransferases and methylation of TJP1 needs further interrogation.

Here, we speculated that DNA methyltransferases contribute to the downregulation of TJP1, thus regulating the development of EMT-mediated MM progression. We show that TJP1 plays an important role in activating EMT in the BM microenvironment, leading to MM metastasis. Tumor progression was significantly suppressed by the MM clinical medicine bortezomib, methylation inhibitor 5-Aza-2'-deoxycytidine (AZA), or TJP1 cDNA, or their combination. These results highlight important molecular aspects that would facilitate the development of therapies for MM.

RESULTS

TJP1 and TJP1-Regulated EMT Were Linked to MM Cell Adhesion and Overall Survival of MM Patients

We previously demonstrated that TJP1 expression is a biomarker of proteasome inhibitor sensitivity in myeloma.24 However, the regulation mechanism of TJP1 in MM progression has yet to be well understood. We analyzed the relationship between TJP1 expression and overall survival in MM patients from the TCGA database (https://hgservier.1.amc.nl/cgi-bin/r2/main.cgi). Notably, we found that upregulation of TJP1 expression reflected a high overall survival rate; thus, TJP1 could be a tumor suppressor gene to MM (p < 0.01) (Figures 1A and S1A). Furthermore, mRNA expression of the TJP1 in healthy donors was higher than in MM patients (p < 0.01) (Figure 1B). Generally, much lower levels of TJP1 were detectable in the MM tissues with higher pathologic stages (Table S1). We also found that the ability of MM cells to adhere to bone marrow stroma cells (BMSCs) was lower than the normal cells (p < 0.01) (Figure 1C). Furthermore, we checked the correlation between the expression level of TJP1 to the adhesion of MM cells to BMSCs in MM cells derived from 40 patients, and the result showed that TJP1 expression was positively correlated with the adhesion of patients’ MM cells to BMSCs (Figure 1D). Since TJP1 has played an important role in EMT, we further investigated the potential expression differences of EMT-like features in MM patients against the normal cells. To investigate the biological functions of TJP1, we analyzed the gene expression profile in MM patients from the GEO database by Gene Set Enrichment Analysis (GSEA). Interestingly, downregulated EMT-like gene sets were significantly enriched in the cells with high TJP1 expression (p < 0.01) (Figures 1E and S1B). Besides, we found positive correlation between TJP1 and E-cadherin mRNA expression in MM patients (Figure 1F). Furthermore, we randomly picked 1 control sample from healthy donors and 2 samples from MM patients to check the mRNA and protein expression of the EMT-related makers. We found that TJP1 and E-cadherin expression were downregulated while the expression of N-cadherin was increased in MM (p < 0.01) (Figures 1G–II). Together, these results showed that EMT was activated by the downregulation of TJP1 to suppress cell adhesion in MM patients.

TJP1 Improves Adhesion Capacity of MM Cells to the BM Stroma via EMT

To further investigate whether TJP1 regulated EMT and cell adhesion to BMSCs in MM, we tested the expression of EMT-related proteins after knockdown or overexpression of TJP1 in the MM1s cells. The results showed that the knockdown of TJP1 resulted into silencing of both the TJP1 and E-cadherin mRNA or protein expression while upregulating the mRNA and protein expression of N-cadherin in

Figure 1. TJP1 and TJP1-Regulated EMT Were Linked to Cell Adhesion and Overall Survival of MM Patients

(A) Relationship between TJP1 expression (Probe 202011_at) and overall survival in MM patients was analyzed in TCGA database on R2 website. (B) mRNA expression of TJP1 between plasma cells from 5 healthy participants and tumor cells from 40 MM patients as assessed by quantitative real-time PCR. The y axis is plotted on a logarithmic scale. Relative mRNA expression of TJP1 in corresponding normal plasma cells was normalized to 1. (C) The adhesion ability of MM cells to BMSCs in MM cells derived from 40 patients, and the correlation between the expression level of TJP1 to the adhesion of patients’ MM cells to BMSCs (Figure 1D). Since TJP1 has played an important role in EMT, we further investigated the potential expression differences of EMT-like features in MM patients against the normal cells. To investigate the biological functions of TJP1, we analyzed the gene expression profile in MM patients from the GEO database by Gene Set Enrichment Analysis (GSEA). Interestingly, downregulated EMT-like gene sets were significantly enriched in the cells with high TJP1 expression (p < 0.01) (Figures 1E and S1B). Besides, we found positive correlation between TJP1 and E-cadherin mRNA expression in MM patients (Figure 1F). Furthermore, we randomly picked 1 control sample from healthy donors and 2 samples from MM patients to check the mRNA and protein expression of the EMT-related makers. We found that TJP1 and E-cadherin expression were downregulated while the expression of N-cadherin was increased in MM (p < 0.01) (Figures 1G–II). Together, these results showed that EMT was activated by the downregulation of TJP1 to suppress cell adhesion in MM patients.
MM1s cells (p < 0.01) (Figures 2A, 2B, and 2E). On the other hand, overexpression of TJP1 increased the mRNA and protein expression of both N-cadherin in MM1s cells (p < 0.01) (Figures 2C, 2D, and 2F). The results of the relationship between TJP1 and EMT were consistent with the data in MM patients. In addition, to better understand the role of the TJP1 gene on suppressing adhesion through the EMT axis, we tested the adhesion capacity of MM cells to BMSCs. The data showed that the adhesion of MM1s was inhibited by TJP1 knockdown but was increased by TJP1 overexpression (p < 0.01) (Figures 2G and 2H). Furthermore, we used EMT inhibitor (C19) to treat MM1s cells bearing silence of TJP1 and showed that the adhesion capacity was rescued by EMT inhibitor (C19). We also used EMT activator TGF-β to confirm in TJP1-overexpressed cells, and these results confirmed that TJP1 regulated adhesion via EMT (Figures 2G and 2H).

**Hypermethylation of the Promoter Region Contributes to Aberrant Low Expression of TJP1 in Myeloma Cells**

A previous study reported that downregulation of TJP1 was related to methylation. Here, we compared the expression of TJP1 in MM patient samples and healthy plasma cells. Our data showed lower mRNA or protein expression of the TJP1 gene in MM patient cells compared to the control group (p < 0.01) (Figures 3A and 3B). In order to identify the CpG islands of TJP1, we obtained the upstream 2,000 bp promoter sequence of TJP1 (selected area: chr15: 29822504–29824503) using the University of California, Santa Cruz (UCSC) Genome Browser (http://genome.ucsc.edu/index.html). Furthermore, we predicted the CpG islands by using the MethPrimer 2.0 (http://www.urogene.org/methprimer2/). Our findings showed that the two CpG islands of TJP1 were located in chr15: 29822791–29823050 (Island 1: 260 bp) and chr15: 29822510–29822715 (Island 2: 206 bp), respectively (Figure S2A). We showed that higher methylation levels existed in 4 MM tissues compared to those in 4 healthy
plasma tissues in the upstream TJP1 promoter region in the tested 20 CpG sites (p < 0.01) (Figures 3C, 3D, and S2B). To further confirm whether TJP1 expression was silenced by methylation, we performed a demethylation test in the MM cells by AZA. As shown in Figures 3A and 3B, AZA treatment significantly increased both the mRNA and protein expression of the TJP1 gene. CpG methylation level was inhibited by AZA treatment (p < 0.01) (Figures 3C and 3D). Furthermore, as TJP1 had three transcriptional start sites (TSSs), corresponding to variants 1, 5, and 7, respectively, within the CpG island (chr15: 29821503–29823012, HG38, UCSC Genome Browser), we designed the universal (TSS1-3 primer to amplify sequences of exon 5, which is included in all variants of TJP1) or specific quantitative real-time PCR primers (TSS1 primer for variant 1 and TSS2 primer for variant 7) to identify which TSSs were reactivated by AZA (Figure S3A). As shown in Figure S3B, the mRNA level of variant 1 or 7 of TJP1 was significantly upregulated by AZA treatment, as well as the mRNA level of TJP1 measured by universal quantitative real-time PCR primers, suggesting the TSS corresponding to TJP1 transcripts 1 and 7 within the CpG island could become activated after AZA treatment.

In addition, we used bisulfite sequencing PCR (BSP) to measure DNA methylation levels of the 2 CpG sites (CpG 6, CpG 12) in the TJP1 promoter. We observed that MM tissues had greater methylation levels compared with the healthy plasma at CpG 6 and CpG 12 sites (Figure 3E). The methylation levels at each of the CpG sites was found to be significantly higher in MM tissues compared with healthy plasma (Figure 3F). The correlation between the methylation rates at CpG 6 and the TJP1 mRNA expression was determined in the 40 MM patient samples. (G) The correlation between the methylation rates at CpG 12 and the TJP1 mRNA expression was determined in the 40 MM patient samples. (H) Different deletion mutants were constructed from fragments ranging from 0 to ~2,000, as shown in the left panel. These deletion mutants together with pGL3-Basic were individually transfected into HEK293T cells, and their promoter activity was measured. Cells were treated with β-galactosidase for 24 h, after which luciferase activity in cell lysates was determined. All data were presented as mean ± SD from 3 independent experiments. Statistical analysis was performed with a paired Student’s t test. *p < 0.01 comparing with control group, ##p < 0.01 comparing with treatment group.
to be negatively correlated with TJP1 expression levels (p < 0.01) (Figures 3F and 3G).

To pinpoint the differential fragment, different deletion mutants were further constructed based on fragments 0 to ~2,000. These deletion mutants, together with pGL3-Basic vector, were individually transfected into HEK293T cells, and the promoter activity was measured. We found that the fragments 0 to ~2,000, 0 to ~566, 0 to ~283, and ~283 to ~2,000 displayed higher promoter activity than other fragments (Figure 3H). Thus, our results demonstrate that the core transcription site of the TJP1 promoter region is located between 0 and ~566, which contains 2 CpG islands at the start of the TJP1 promoter. Furthermore, low luciferase activities were observed when the TJP1 promoter was methylated, especially in the fragments in the 2 CpG islands, indicating that methylation suppresses the promoter activity (Figure 3H).

**DNMT1-Mediated Hypermethylation of TJP1 Promoter Regulates EMT**

To evaluate whether the expression of TJP1 was upregulated by methylation, including DNMT1, DNMT3a, or DNMT3b, we conducted both quantitative real-time PCR and western blot analysis and showed that overexpressed DNMT1 downregulated the mRNA and protein expression of the TJP1 gene as well as upregulated the EMT (p < 0.01) (Figures 4A and 4B). Neither DNMT3a nor DNMT3b affected the expression of TJP1 or EMT (Figure 4A). The CpG methylation level of the TJP1 promoter also increased with the DNMT1 overexpression (p < 0.01) (Figure 4C). To better understand the role of DNMT1 in the regulation of cell adhesion through TJP1, we tested the adhesion capacity of MM cells to BMSCs with DNMT1 overexpression. Our data showed that the adhesion of MM1s cells was inhibited by DNMT1 overexpression but was rescued by TJP1 overexpression (p < 0.01) (Figure 4D). On the other hand, we demonstrated that DNMT1 silencing could upregulate the mRNA and protein expression of TJP1 but downregulate EMT (p < 0.01) (Figures 4E and 4F). The CpG methylation level of TJP1 also decreased with the downregulation of DNMT1 (p < 0.01) (Figure 4G). Furthermore, the adhesion of MM1s was increased by DNMT1 knockdown but was rescued by TJP1 knockdown (p < 0.01) (Figure 4H). Finally, analysis of the relationship between DNMT1 and TJP1 expression in the MM patient database showed significant negative correlation between DNMT1 and TJP1 (p < 0.01) (Figure 4B). Interestingly, we also found that increased DNMT1 expression was associated with low overall survival rate in the MM patients, and upregulated EMT-like gene sets were significantly enriched in the patients with high DNMT1 expression (p < 0.01) (Figures 4C and 4D). These observations suggest that DNMT1 regulates the MM cell adhesion via methylation of the TJP1 gene.

**Effects Associated with the Use of Methylation Inhibitor and/or TJP1 Overexpression with Bortezomib in MM**

To examine whether methylation inhibitor AZA and/or TJP1 overexpression affect drug susceptibility of MM, we used AZA and/or adeno-associated viral (AAV) vector TJP1-cDNA with bortezomib for treatment. MM cells were sorted from patient samples and treated by AZA and/or TJP1 cDNA with bortezomib, which was an anti-cancer agent used in various stages of MM treatment. The results showed that the cell proliferation was inhibited by bortezomib, and AZA or TJP1 cDNA with bortezomib. The combination of AZA, TJP1-cDNA, and bortezomib robustly inhibited cell viability (p < 0.01) (Figure 5A). Furthermore, treatment of tumor-bearing severe combined immunodeficiency (SCID) mice with bortezomib, AZA, or TJP1 cDNA or their combination showed a decrease in the tumor volume in subcutaneous MM models (Figure 5B). We also showed that the use of bortezomib, AZA, or TJP1 cDNA or their combination prolonged the survival time of MM orthotopic models. However, the combination therapy yielded the most significant effect (p < 0.001) (Figure 5C).

**DISCUSSION**

TJP1 protein is widely used as a maker of tight junctions and is known to promote tumor development in various types of cancer. Our recent study identified TJP1 as a biomarker for the susceptibility of proteasome inhibitors in MM patients. Downregulation of TJP1 expression is associated with disrupted epithelial intercellular junctions alongside E-cadherin during developmental EMT. The adhesion properties are important indicators of malignancy and spread of MM. However, data on whether TJP1 or EMT regulates adhesion in the mediation of MM progression are still limited. Here, we show that TJP1 and EMT are regulated by TJP1 and are linked to overall survival of MM patients. Methylation of the promoter region contributes to the aberrant low expression of TJP1, which then increases EMT but decreases the adhesion of MM cells. Furthermore, we investigated the effect of upregulated methylation of the TJP1 promoter by DNMT1 on the low expression of TJP1 in MM cells. Lastly, we treated MM cells and mice models by methylation inhibitor and/or TJP1-cDNA with bortezomib, and the results showed that a combination regimen of methylation inhibitor/TJP1-cDNA with bortezomib was the most effective in MM. It is worth mentioning that TJP1 mRNA and protein expression were much lower in MM compared with healthy samples. Thus, reduced TJP1 expression may be a molecular marker for poor prognosis of MM.

Most of the studies focused on how TJP1 regulates proliferation and cellular permeability to modulate proteasome capacity. We previously demonstrated that TJP1 modulates proteasome capacity and proteasome inhibitor sensitivity in MM via EGFR/JAK1/STAT3 signaling. However, the mechanism of action of the TJP1 in cancer progression is yet to be investigated. EMT is often observed in primary tumor at the cancer invasion front. Cancer cells lose their adhesive properties and acquire an enhanced mobility by undergoing EMT. Recently, junctional adhesion molecules (JAMs), adhesion and transmigration regulatory elements, have been reported to play a critical role in regulating tumor progression. MM progression occurs when there is inability to control MM cell adhesion, as well as ability of the MM cells to egress from the BM to the bloodstream and into new BM niches. TJP1 plays an important role in the EMT machinery, and alternative splicing of TJP1 promotes actin stress fiber assembly during EMT. In our study, we demonstrated that TJP1 and cell adhesion were significantly inhibited and EMT was elevated in MM.
The EMT activator TGF-β attenuated the induced adhesion of MM by overexpression of TJP1, whereas the EMT inhibitor reversed the inhibition of cell adhesion of MM after TJP1 silencing. Therefore, the TJP1 gene plays an important role in the MM cell adhesion via EMT.

Whereas previous studies have interrogated TJP1 regulation of downstream pathways like EMT and tumorigenesis, few studies have evaluated the factors that regulate TJP1 expression. DNA methylation occurs by invertible addition of a methyl group to the cytosine residue involved in methylation of the gene. Among them, DNMT1 was the only one shown to modulate TJP1 expression by affecting the CpG methylation of the promoter region in MM. The regulation of TJP1 by DNMT1 affects the EMT pathway, thus regulating MM cell adhesion.

Our data clearly confirmed that epigenetic modifications could affect TJP1 expression. The expression change of TJP1 regulates cell adhesion via EMT in MM. The methylation state of DNA is maintained in a dynamic homeostasis by DNMTs and translocation proteins (TETs).
DNMTs catalyze and maintain the methylation state of CpGs in DNA, while the TETs induce demethylation. Although our results found significant upregulation of DNMT expression in MM and direct interactions of DNMT1 with the TJP1 promoter, the role of TETs in regulating TJP1 promoter methylation in MM is still undefined. Therefore, further studies will be necessary to evaluate whether TETs mediate methylation alteration of the TJP1 gene in MM.

In summary, this study robustly demonstrates that TJP1 expression is downregulated in MM clinical samples. TJP1 downregulation modulates EMT, which then suppresses the cell adhesion capacity, thus promoting tumor progression. In addition, the promoter region of the aberrantly expressed TJP1 was shown to be highly methylated by DNMT1 in MM. Methylation rates were negatively correlated with TJP1 mRNA expression levels in both MM cell lines and clinical samples. Methylation inhibitor/activator could rescue and reverse the phenomenon. Moreover, combination of methylation inhibitor and TJP1-cDNA with bortezomib may yield superior outcomes in the treatment of myeloma. Our ongoing studies will further address the inducing factors of DNMT1 in the regulation TJP1 methylation in myeloma.

MATERIALS AND METHODS

Human Cell Lines and Primary Cells
The human MM cell line MM1s (ATCC: CRL-2974) was cultured in RPMI 1640, supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). The study was approved by the Sun Yat-sen University Institutional Review Board, and written informed consent was obtained from all the patients in accordance with the Declaration of Helsinki. The demographic and clinical features of the patients are summarized in Table S1. Primary MM cells were obtained from BM samples using CD138 micro-bead selection (Milteny Biotec, Auburn, CA, USA) with more than 90% purity. The purity was confirmed by flow cytometric analysis with monoclonal antibody against human CD38-PE (BD Biosciences, San Jose, CA, USA). BMSC and plasma cells were obtained from healthy volunteers after Ficoll-Hypaque density sedimentation.

Quantitative Real-Time PCR
To detect mRNA expression in MM and normal cells, we performed quantitative real-time PCR as described previously. The qPCR primer TJP1 TSS1-3 primer was used to detected all transcripts of TJP1 located in the exon 5 region (TJP1 TSS1-3 sequence: Forward primer: 5’-ACCAGTAAGTCGTCCTGATCC-3’; Reverse primer: 5’-TCGGCCAAATCTTCTCATTCC-3’). Two other TJP1 TSS1 and TSS2 primers, which were used to detect TJP1 variant 1 (TJP1 TSS1) and variant 7 (TJP1 TSS2) uniquely, are listed in Table S2.
Western Blot
Protein lysates were prepared and analyzed as described previously. Primary antibodies anti-GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) (1:5,000), anti-DNMT1 (1:1,000), anti-TJP1 (1:500), anti-E-cadherin (1:1,000), and anti-N-cadherin (1:500) from Cell Signaling Technology (Danvers, MA, USA) were used.

Cell Viability Assays
The tetrazolium reagent WST-1 was used to determine cell viability according to the manufacturer’s protocol and as previously described.

Adhesion Assay
A confluent monolayer of the BMSCs (passages 2–5) was generated by plating 1 × 10^5 cells/well in 96-well plates for 24 h. MM1s cells were cultured for 24 h, then labeled with fluorescent calcein-AM (1 μg/mL for 1 h), washed, and a suspension of 0.5 × 10^6 cells/mL was prepared. MM1s cells or stroma were separately treated with E-cadherin-blocking Ab for 1 h and then washed before being used in the adhesion assay. 100 μL of the MM cell suspension was added to the BMSCs and then incubated for 1 h. Non-adherent cells were washed, and adhesion was detected by measuring the fluorescence intensity in the wells using a plate-reader fluorometer Infiniti M200 (excitation/emission, 485/520 nm; Tecan, Baldwin Park, CA, USA).

Immunofluorescence (IF) Staining
IF staining was performed according to the protocol. We incubated the slides with human-specific anti-E-cadherin monoclonal antibody (1:200) (Abcam, Cambridge, MA, USA) for 90 min at room temperature. Thereafter, the appropriate secondary antibodies (1:5,000) were applied and incubated for 30 min. The IF staining was assessed by combining measurements of the intensity and extent of immunopositivity (60×).

Animal Models for MM In Vivo
All animal experiments were approved by the Animal Ethics Committee of Sun Yat-sen University and performed in accordance with the guidelines of the Animal Care and Use Committee of Sun Yat-sen University. In total, 30 male, non-obese diabetic (NOD)-SCID mice (7–9 weeks old, median weight 28 g) were obtained from the Sun Yat-sen University animal center. An in vivo xenograft model was developed in immunodeficient mice by injecting MM1s cells. Myeloma xenograft tumors were generated by injecting 5 × 10^6 cells resuspended in Matrigel (BD Biosciences) subcutaneously in the right flank of mice. Mice were blindly randomized into five groups (n = 3) of the control, bortezomib, bortezomib/ZA, bortezomib/TJP1-cDNA, or bortezomib/ZA/TJP1-cDNA. For subcutaneous injection of tumor cells to detect the tumor volumes, the tumor volumes were measured every 3 days and calculated as follows (length × width^2)/2. Ethical endpoints were defined as a tumor volume of 400 mm^3 or 20% loss of original body weight. For studies of the survival time of MM orthotopic models, a total of 3 × 10^6 MM1s cells were injected into mice via tail veins, and mice were inspected daily for any signs of distress. Mice were blindly randomized into five groups (n = 3) of control, bortezomib, bortezomib/ZA, bortezomib/TJP1-cDNA, or bortezomib/ZA/TJP1-cDNA. The survival duration of MM orthotopic mice was recorded. All mice were euthanized by asphyxiation with CO2 followed by cervical dislocation, away from other animals.

AZA, EMT Inhibitor (C19), and TGF-β Treatment in MM Cells
After growing to about 40%–50% confluence, the cells were treated with inhibitors of DNA methylation AZA (Sigma, Shanghai, China),
EMT inhibitor (C19, MedChemExpress, Monmouth Junction, NJ, USA), or EMT activator TGF-β (Sigma), dissolved in PBS, from a serial dilution of 3.0 μM, 10 μM, or 10 ng/mL, respectively. The media exchange and reagent treatments were performed on cells for 2 days. We used untreated cells as the study control.

**Statistical Analysis**

Data were analyzed and represented using GraphPad Prism 7 software. Error bars represent the mean ± standard deviation (SD) for triplicate measurements from at least 3 independent experiments. Differences between the 2 groups were analyzed by the Student’s t test. Survival curves were created using the Kaplan-Meier method, with the log-rank test used to assess significance. p values < 0.05 were considered statistically significant.

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at https://doi.org/10.1016/j.omto.2020.10.004.

**AUTHOR CONTRIBUTIONS**

L.Q., Y.Z., and X.D.Z. designed the experiments. M.L., L.Q., S.C., and J.B.X. performed the experiments. X.R.S., Z.X.D., and X.D.Z. analyzed data. Y.Z. provided essential research reagents. J.L., T.L.F., and Z.Y.M. provided and reviewed pathological data. S.N.C. and L.Y.Z. edited the manuscript. L.Q. and X.D.Z. directed the research and wrote the manuscript.

**CONFLICTS OF INTEREST**

The authors declare no competing interests.

**ACKNOWLEDGMENTS**

This work was supported in part by the National Natural Science Foundation of China, China (grant nos. 81970191 and 81970193); Guangdong Basic and Applied Basic Research Foundation, China (grant no. 2019A1515011327); Fundamental Research Funds for the Central Universities, Sun Yat-sen University, China (grant nos. 19ykpy149 and 19ykpy39); and Medical Scientific Research Foundation of Guangdong Province, China (grant no. A2018031).

**REFERENCES**

1. Mizuno, N., Hideshima, T., and Anderson, K.C. (2015). Novel therapeutic strategies for multiple myeloma. Exp. Hematol. 43, 732–741.

2. Tai, Y.T., Dillon, M., Song, W., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., et al. (2008). Anti-CNI humanized monoclonal antibody HuLac63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood J12, 1329–1337.

3. Acloque, H., Thiery, J.P., and Nieto, M.A. (2008). The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. EMBO Rep. 9, 322–326.

4. Shenoy, A.K., and Lu, J. (2016). Cancer cells remodel themselves and vasculature to overcome the endothelial barrier. Cancer Lett. 380, 534–544.

5. Jolly, M.K., Ware, K.E., Gilja, S., Somarelli, J.A., and Levine, H. (2017). EMT and MET: necessary or permissive for metastasis? Mol. Oncol. 11, 755–769.

6. Roccaro, A.M., Mishima, Y., Sacco, A., Moschetta, M., Tai, Y.T., Shi, J., Zhang, Y., Reagan, M.R., Huynh, D., Kawano, Y. et al. (2015). CXCR4 Regulates Extramedullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 12, 622–635.

7. Ryu, J., Koh, Y., Park, H., Kim, D.Y., Kim, D.C., Byun, J.M., Lee, H.J., and Yoon, S.S. (2016). HighlyExpressed Integrin-a8Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse. Mol. Cells 39, 898–908.

8. Azab, A.K., Hu, J., Quang, P., Azab, F., Pitsillides, C., Awadh, R., Thompson, B., Maeso, P., Sun, J.D., Hart, C.P., et al. (2012). Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119, 5782–5794.

9. Ullah, T.R. (2019). The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond. J. Bone Oncol. 17, 100253.

10. Chirillo, R., Aversa, I., Di Vito, A., Salatino, A., Battaglia, A.M., Sacco, A., Di Sanzo, M.A., Fanelli, M.C., Quaresima, B., Palmieri, C., et al. (2020). FH-mediated ROS Dysregulation Promotes CXCL12/CXCR4 Axis Activation and EMT-Like Transdifferentiation in Erythroleukemia K562 Cells. Front. Oncol. 10, 698.

11. Bianchi, G., Richardson, P.A., and Anderson, K.C. (2015). Promising therapies in multiple myeloma. Blood 126, 300–310.

12. Guang, M.H.Z., McCann, A., Bianchi, G., Zhang, L., Dowling, P., Bazou, D., O’Gorman, P., and Anderson, K.C. (2018). Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’. Leuk. Lymphoma 59, 542–561.

13. Zhang, J., Tian, X.J., and Xing, J. (2016). Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks. J. Clin. Med. 5, 41.

14. Laing, J.G., Koval, M., and Steinberg, T.H. (2005). Association with ZO-1 correlates with plasma membrane partitioning in truncated connexin45 mutants. J. Membr. Biol. 207, 45–53.

15. Hoover, K.B., Liao, S.Y., and Bryant, P.J. (1998). Loss of the tight junction MAGUK protein ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am. J. Pathol. 153, 1767–1773.

16. González-Mariscal, L., Tapia, R., and Chamorro, D. (2008). Crosstalk of tight junction components with signaling pathways. Biochim. Biophys. Acta 1778, 729–756.

17. Martin, T.A., and Jiang, W.G. (2009). Loss of tight junction barrier function and its role in cancer metastasis. Biochim. Biophys. Acta 1788, 872–891.

18. Kaihara, T., Kawamata, H., Imura, J., Fujii, S., Kitajima, K., Ometohara, F., Maeda, N., Nakamura, T., and Fujimori, T. (2003). Redistribution and ZO-1 reexpression in liver-metastasized colorectal cancer: possible association with epidermal growth factor receptor-induced tyrosine phosphorylation of ZO-1. Cancer Sci. 94, 166–172.

19. Kleef, J., Shi, X., Bode, H.P., Hoover, K., Shrikhande, S., Bryant, P.J., Kore, M., Büchler, M.W., and Friess, H. (2001). Altered expression and localization of the tight junction protein ZO-1 in primary and metastatic pancreatic cancer. Pancreas 23, 259–265.

20. Ni, S., Xu, L., Huang, J., Feng, J., Zha, H., Wang, G., and Wang, X. (2013). Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 6, 2887–2895.

21. Smalley, K.S., Braford, P., Haas, N.K., Brandner, J.M., Brown, E., and Herlyn, M. (2005). Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am. J. Pathol. 166, 1541–1554.

22. Kim, I.E., Won, M., Lee, S.G., Park, C., Song, C.H., and Kim, K.K. (2019). RBM47-regulated alternative splicing of TJP1 promotes actin stress fiber assembly during epithelial-to-mesenchymal transition. Oncogene 38, 6521–6536.

23. Ruiz, I., and Hawley, R.G. (2017). Increased expression of the tight junction protein TJP1/ZO-1 is associated with upregulation of TAZ-TEAD activity and an adult tissue stem cell signature in carfizomb-resistant multiple myeloma cells and high risk multiple myeloma patients. Oncoscience 4, 79–94.

24. Zhang, X.D., Baladandayuthapani, V., Lin, H., Mulligan, G., Li, B., Esseltine, D.W., Qi, L., Xu, J., Hunziker, W., Barlogie, B., et al. (2016). Tight Junction Protein 1 Modules Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29, 639–652.

25. Ziller, M.J., Gu, H., Müller, F., Donahue, J., Tsai, L.T., Kohlbacher, O., De Jager, P.L., Rosen, E.D., Bennett, D.A., Bernstein, B.E., et al. (2013). Charting a dynamic DNA methylation landscape of the human genome. Nature 500, 477–481.

26. Weber, M., Davies, J.J., Wittig, D., Oakley, E.J., Haase, M., Lam, W.L., and Schübel, D. (2005). Chromosome-wide and promoter-specific analyses identify sites of
differential DNA methylation in normal and transformed human cells. Nat. Genet. 37, 853–862.

27. Cen, J., Shen, J., Wang, X., Kang, H., Wang, L., Sun, L., Li, Y., and Yu, L. (2013). Association between lymphoma prognosis and aberrant methylation of ID4 and ZO-1 in bone marrow and paraffin-embedded lymphoma tissues of treatment-naive patients. Oncol. Rep. 30, 455–461.

28. Easwaran, H., Tsai, H.C., and Baylin, S.B. (2014). Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716–727.

29. Ahuja, N., Easwaran, H., and Baylin, S.B. (2014). Harnessing the potential of epigenetic therapy to target solid tumors. J. Clin. Invest. 124, 56–63.

30. Böck, J., Appenzeller, S., Haerle, L., Schneider, T., Gehrig, A., Schroder, J., Rost, S., Wolf, B., Bartram, C.R., Sutter, C., and Haaf, T. (2018). Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients. Int. J. Cancer 143, 1416–1425.

31. Smith, E.M., Boyd, K., and Davies, F.E. (2010). The potential role of epigenetic therapy in multiple myeloma. Br. J. Haematol. 148, 702–713.

32. Wu, X.Y., Chen, H.C., Li, W.W., Yan, J.D., and Lv, R.Y. (2020). DNMT1 promotes cell proliferation via methylating hMLH1 and hMSH2 promoters in EGFR-mutated non-small cell lung cancer. J. Biochem. 168, 151–157.

33. Chen, T., Hevi, S., Gay, F., Tsujimoto, N., He, T., Ueda, Y., and Li, E. (2007). Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat. Genet. 39, 391–396.

34. Yoo, J., Kim, J.H., Robertson, K.D., and Medina-Franco, J.L. (2012). Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor. Adv. Protein Chem. Struct. Biol. 87, 219–247.

35. Wong, K.K., Lawrie, C.H., and Green, T.M. (2019). Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia. Biomark. Insights 14, 1177219198464544.

36. Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.T., Mazitschek, R., Hadeshima, T., and Anderson, K.C. (2017). HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia 31, 2670–2677.

37. Tsai, K.W., Kuo, W.T., and Jeng, S.Y. (2018). Tight Junction Protein 1 Dysfunction Contributes to Cell Motility in Bladder Cancer. Anticancer Res. 38, 4607–4615.

38. Zeisberg, M., and Neilson, E.G. (2009). Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119, 1429–1437.

39. Zhang, X.D., Wang, Y., Wang, Y., Zhang, X., Han, R., Wu, J.C., Liang, Z.Q., Gu, Z.L., Han, F., Fukunaga, K., and Qin, Z.H. (2009). p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum. Autophagy 5, 339–350.

40. Balda, M.S., Garrett, M.D., and Matter, K. (2003). The ZO-1-associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density. J. Cell Biol. 160, 423–432.

41. De Wever, O., Pauwels, P., De Craene, B., Sabbah, M., Emami, S., Redeuilh, G., Gespach, C., Bracke, M., and Berx, G. (2008). Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem. Cell Biol. 130, 481–494.

42. Bradford, P.F., Siebermann, C., Nourshargh, S., Ody, C., Lusczynska, F.W., Rainier, G.E., Nash, G.B., Miljkovic-Licina, M., Aurrand-Lions, M., and Imhof, B.A. (2007). JAM-C regulates unidirectional monocyte transendothelial migration in inflammation. Blood 110, 2545–2555.

43. Ghobrial, I.M. (2012). Myeloma as a model for the process of metastasis: implications for therapy. Blood 120, 20–30.

44. Stelzer, Y., Shivalila, C.S., Soldner, F., Markoulaki, S., and Jaenisch, R. (2015). Tracing dynamic changes of DNA methylation at single-cell resolution. Cell 163, 218–229.

45. Bird, A.P. (1996). The relationship of DNA methylation to cancer. Cancer Surv. 28, 87–101.

46. Qi, L., Sun, X., Li, F.E., Zhu, B.S., Braun, F.K., Liu, Z.Q., Tang, J.L., Wu, C., Xu, F., Wang, H.H., et al. (2015). HMG1B Promotes Mitochondrial Dysfunction-Triggered Striatal Neurodegeneration via Autophagy and Apoptosis Activation. PLoS ONE 10, e0142901.

47. Steinberg, Z., Myera, C., Heim, V.M., Lathrop, C.A., Rebustini, I.T., Stewart, J.S., Larsen, M., and Hoffman, M.P. (2005). FGF2R2b signaling regulates ex vivo submandibular gland epithelial cell proliferation and branching morphogenesis. Development 132, 1223–1234.